Committee Unblinds Phase III Zytiga Study
USPSTF and ACS Recommend Less Frequent Cervical Cancer Screenings and Pap Smears
Tobacco Control and Prevention Saved 795,000 Lives Between 1975-2000, Study Shows
Five-year Childhood ALL Survival Increased To 90.4 Percent by 2005
Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit
Study: Freezing Secondary Tumors Helpful in Metastatic Breast Cancer
Women Who Received CMF Chemotherapy Score Lower On Cognitive Skill Exams
Three Studies Demonstrate Oncotype DX Test Effectiveness
ACG Highlights Link Between Obesity and Colorectal Cancer
Olaparib Study Demonstrates No Changes In Overall Survival
Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study
Trials Approved by NCI CTEP For the Month of March
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
